We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood and Saliva Samples Can Be Used to Detect Genetic Markers for Liver Cancer

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Illustration
Illustration

Doctors examining the markers of liver cancer have found that the disease can be recognized by RNA fragments in saliva and blood.

This discovery by doctors at the RUDN University (Moscow, Russia) is significant because of the need to develop ways to find liver cancer in people at risk before it is too late. Liver cancer is less common than other cancers, but it has lower survival rates. Sometimes it appears suddenly, but in most cases, it is preceded by other liver diseases. For example, liver cirrhosis due to hepatitis C. However, in this case, the development of liver cancer can occur imperceptibly. It is difficult to diagnose it in the early stages.

RUDN University doctors have found that microRNA (small sequences of RNA that do not encode genes but are involved in the regulation of their expression) can be a marker of liver cancer. Doctors took blood and saliva samples from 29 patients with cirrhosis, 24 patients with liver cancer and 21 healthy volunteers and compared the expression level of 10 different microRNAs in the samples.

Seven microRNAs that were found in the blood plasma outside the exosomes (the vesicles secreted by cells) were associated with liver cancer. Three of them were also found in saliva. This can be important for diagnosis, since saliva analysis is significantly simpler as the collection of the sample does not need a professional, the patients can do it themselves. The microRNAs found inside the exosomes may become even more effective marker of liver cancer. For them, saliva is even preferable for analysis than blood. Therefore, depending on what biological material is available, it is possible to estimate the development of liver cancer by exosomal and non-exosomal microRNAs.

"The incidence rate, along with other factors, including the reluctance of at-risk patients to systematically come to the research center for blood sampling, complicates the collection of samples to identify markers for early diagnosis,” said Alisa Petkevich, a researcher at the RUDN University. “A possible solution could be the use of biomaterial that does not require medical personnel for its collection, such as saliva. We proved that saliva is a promising source of exosomal and non-exosomal microRNAs. Exosomal microRNAs have shown a strong association with primary liver cancer in saliva samples.”

Related Links:
RUDN University 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Quality Control Material
Multichem U
New
3-Part Diff Hematology Analyzer
HEMIX 3-60
New
Modular Clinical Chemistry Analyzer
CMD 800X1/CMD 800iX1

Print article

Channels

Molecular Diagnostics

view channel
Image: Nanopore devices offer direct analysis of DNA/RNA in-real time (Photo courtesy of Oxford Nanopore)

Pocket-Sized Devices Enable Real-Time DNA and RNA Sequencing Anywhere

DNA and RNA sequencing can answer a range of biological questions, providing information on pathogen identity, genetic disease risk or how an organism has evolved. Now, a new generation of sensing technology... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio's Belgian Acquisition Targets Neurodegenerative Diagnostics

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.